Letter by McCaw et al Regarding Article, "The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease"

Circulation. 2021 Jan 5;143(1):e1-e2. doi: 10.1161/CIRCULATIONAHA.120.050723. Epub 2020 Dec 30.

Authors

Zachary R McCaw¹, Garrett Fitzmaurice^{2

3}, Lee-Jen Wei³

Affiliations

¹ Google, Mountain View, CA (Z.R.M).
² Laboratory for Psychiatric Biostatistics, McLean Hospital, Belmont, MA (G.F.).
³ Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA (G.F., L.-J.W.).

PMID: 33378233
DOI: 10.1161/CIRCULATIONAHA.120.050723

No abstract available

Publication types

Letter
Comment

MeSH terms

Aspirin / adverse effects
Factor Xa Inhibitors / adverse effects
Humans
Platelet Aggregation Inhibitors / adverse effects
Rivaroxaban* / adverse effects
Vascular Diseases*

Substances

Factor Xa Inhibitors
Platelet Aggregation Inhibitors
Rivaroxaban
Aspirin